Test UB-421 plus chidamide to reduce HIV hidden virus
Part of Infections clinical trials.
This Phase 2 study tests whether UB-421 combined with chidamide can shrink or control the “HIV reservoir,” the hidden HIV in the body that standard treatment may not fully eliminate. It’s mainly for people already on stable HIV medicines with very well-controlled viral levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HIV-1 infection confirmed in your medical records (signed diagnosis history).
- You are an adult (18+) and meet the body-weight cutoff (≥50 kg if male, ≥45 kg if female).
- You’ve been on HIV treatment for over 1 year that includes 2 NRTIs plus at least 1 of these: NNRTI, protease inhibitor, integrase inhibitor, or an entry inhibitor.
- Your HIV viral load has been very low (below 50 copies/mL) for at least 12 months, with stable control.
- If you could become pregnant: you are not pregnant now and agree to use two forms of birth control; if you’re able to have children, you and your partner must use two methods during the study (no breastfeeding).
- You can provide informed consent and have had no major recent immune/health issues that would interfere with study results.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests UB-421 added to a customized (optimized) set of existing HIV medicines for people with HIV that is resistant to multiple drugs. It may help reduce the virus more effectively when standard treatments have not been enough.
This study tests whether giving very high doses of your current HIV meds can flush out hidden HIV that stays in the body even when the virus is undetectable. It might help find a way to reduce or eliminate the reservoir of latent HIV.
This study tests whether combining immune checkpoint inhibitors with chidamide can help achieve a functional cure for HIV. It is for people living with HIV who are already on effective antiretroviral therapy and have a stable, well-controlled viral load.
This trial tests a combination of two drugs that may 'wake up' hidden HIV in your body's cells, so that your immune system or other treatments can then eliminate it. The goal is to shrink the HIV reservoir that remains even when you're on antiretroviral therapy.
This trial tests a combination of two experimental drugs designed to 'shock and kill' hidden HIV in your body. It is for people with HIV-1 subtype B who are on successful ART and want to explore a potential step toward a cure.
This trial tests a new combination of three medications, lenacapavir, teropavimab, and zinlirvimab, for people with HIV who currently have undetectable virus levels on a stable oral treatment. The goal is to see if these drugs can keep the virus suppressed, possibly allowing a simpler treatment plan.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.